Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or …
Over the last 12 months, insiders at Heron Therapeutics, Inc. have bought $0 and sold $0 worth of Heron Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Heron Therapeutics, Inc. have bought $3.69M and sold $187,403 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 25,000 shares for transaction amount of $27,250 was made by Forbes William P (EVP, Chief Development Officer) on 2023‑11‑17.
2023-11-17 | Forbes William P | EVP, Chief Development Officer | 25,000 0.0179% | $1.09 | $27,250 | +121.10% | ||
2023-11-16 | Collard Craig A | Chief Executive Officer | 150,000 0.1065% | $0.92 | $137,970 | +162.87% | ||
2023-11-16 | Duarte Ira | EVP, Chief Financial Officer | 85,000 0.0584% | $0.89 | $75,599 | +162.87% | ||
2023-11-16 | Forbes William P | EVP, Chief Development Officer | 50,000 0.0363% | $0.94 | $46,995 | +162.87% | ||
2023-07-21 | Morgan Adam | director | 2.49M 2.0703% | $1.37 | $3.41M | +61.59% | ||
2022-05-03 | Sale | MANHARD KIMBERLY | EVP, Drug Development | 1,504 0.0015% | $4.76 | $7,154 | -38.95% | |
2021-12-21 | Sale | Christian Waage | director | 300 0.0003% | $9.73 | $2,920 | -56.73% | |
2021-12-21 | Sale | Johnson Craig A | director | 250 0.0002% | $9.73 | $2,432 | -56.73% | |
2021-09-21 | Sale | Christian Waage | director | 600 0.0006% | $12.31 | $7,384 | -54.08% | |
2021-09-21 | Sale | Johnson Craig A | director | 500 0.0005% | $12.30 | $6,148 | -54.08% | |
2021-06-21 | Sale | Christian Waage | director | 600 0.0006% | $15.20 | $9,118 | -40.10% | |
2021-06-21 | Sale | Johnson Craig A | director | 500 0.0005% | $15.20 | $7,601 | -40.10% | |
2021-05-03 | Sale | MANHARD KIMBERLY | EVP, Drug Development | 3,058 0.0032% | $17.66 | $54,017 | -39.34% | |
2021-04-15 | Sale | Christian Waage | director | 600 0.0006% | $17.51 | $10,508 | -38.97% | |
2021-04-06 | Sale | Johnson Craig A | director | 500 0.0005% | $17.22 | $8,610 | -33.90% | |
2021-01-14 | Sale | Szekeres David Leslie | EVP, Chief Operating Officer | 1,654 0.0018% | $18.09 | $29,920 | -29.12% | |
2021-01-08 | Sale | Szekeres David Leslie | EVP, Chief Operating Officer | 7,142 0.0039% | $9.83 | $70,219 | -32.19% | |
2020-12-22 | Sale | MANHARD KIMBERLY | EVP, Drug Development | 20,000 0.0176% | $16.50 | $330,000 | -32.95% | |
2020-05-01 | Sale | MANHARD KIMBERLY | Executive VP, Drug Development | 2,316 0.0013% | $6.98 | $16,176 | +25.16% | |
2019-11-29 | Sale | MANHARD KIMBERLY | Executive VP, Drug Development | 48,000 0.0274% | $13.00 | $624,000 | -35.68% |
Morgan Adam | director | 6986744 4.5866% | $16.21M | 1 | 0 | +61.59% |
TANG KEVIN C | director | 5799810 3.8074% | $13.46M | 19 | 1 | +4.62% |
Collard Craig A | Chief Executive Officer | 186496 0.1224% | $432,670.72 | 1 | 0 | +162.87% |
RIEPENHAUSEN PETER | director | 179332 0.1177% | $416,050.24 | 2 | 0 | |
Quart Barry D | Chief Executive Officer | 94652 0.0621% | $219,592.64 | 3 | 4 | <0.0001% |
$5,911,307 | 70 | -1.38% | $309.77M | |
Heron Therapeutics, Inc. (HRTX) | $109,415,500 | 33 | 18.13% | $353.41M |
$41,446,394 | 27 | 12.91% | $340.18M | |
$14,865,077 | 18 | -28.56% | $389.16M | |
$49,750,490 | 17 | 37.19% | $307.1M |
Increased Positions | 69 | +31.94% | 8M | +6.9% |
Decreased Positions | 86 | -39.81% | 15M | -12.45% |
New Positions | 25 | New | 5M | New |
Sold Out Positions | 37 | Sold Out | 6M | Sold Out |
Total Postitions | 199 | -7.87% | 115M | -5.54% |
Rubric Capital Management Lp | $65,982.00 | 17.58% | 26.71M | 0 | 0% | 2024-12-31 |
Blackrock, Inc. | $21,219.00 | 5.65% | 8.59M | +56,175 | +0.66% | 2024-12-31 |
Adage Capital Partners Gp, L.L.C. | $20,995.00 | 5.59% | 8.5M | -350,000 | -3.96% | 2024-12-31 |
Vanguard Group Inc | $20,149.00 | 5.37% | 8.16M | -562,567 | -6.45% | 2024-12-31 |
Velan Capital Investment Management Lp | $17,257.00 | 4.6% | 6.99M | 0 | 0% | 2024-12-31 |
Tejara Capital Ltd | $11,514.00 | 3.07% | 4.66M | -644,269 | -12.14% | 2024-12-31 |
Palisade Capital Management, Lp | $9,698.00 | 2.58% | 3.93M | -65,889 | -1.65% | 2024-12-31 |
D. E. Shaw & Co., Inc. | $9,198.00 | 2.45% | 3.72M | -660,971 | -15.07% | 2024-12-31 |
State Street Corp | $7,771.00 | 2.07% | 3.15M | -46,243 | -1.45% | 2024-12-31 |
Point72 Asset Management, L.P. | $7,597.00 | 2.02% | 3.08M | +3M | New | 2024-12-31 |